BUSINESS CASE FOR LEVEL 2 SPECIALIST NEURO … CASE FOR LEVEL 2 SPECIALIST NEURO-REHABILITATION BEDS...
Transcript of BUSINESS CASE FOR LEVEL 2 SPECIALIST NEURO … CASE FOR LEVEL 2 SPECIALIST NEURO-REHABILITATION BEDS...
1
Add
BUSINESS CASE FOR LEVEL 2 SPECIALIST NEURO-REHABILITATION BEDS : SLIDE PACK & FINANCIAL MODEL
V8
June 2015
2
Add • Executive summary Slides 3 - 5
• Business Case on a Page Slide 6
• Model methodology Index/ Summary Slide 7
A. Methodology for calculating DTOC, beds and costs: Slide 8
1. Nos. of Neuro Rehab patients experiencing DTOC Slide 9
2. Nos. of required Neuro Rehab beds Slide 10
3. Cost of Level 2 Neuro Rehab beds Slide 11
• Summary methodology for investment Slide 12
B. Benefits Methodology – Steps: Slide 13
1. Calculate # of Neuro Rehab patients experiencing DTOC per provider Slide 14
2. Calculate average bed days lost per DTOC Slide 15
3. Summary of benefits - Neuro-rehab DTOC Slide 16
4. Summary of Benefits – ongoing care Slide 17
• Funding Arrangements – Options Appraisal Slide 18 to 31
Index
3
Add Specialist rehabilitation is the total active care (assessment, treatment and management) of patients with a disabling condition, and their families, by a multi-professional team who have undergone recognised specialist training in rehabilitation, led /supported by a consultant trained and accredited in rehabilitation medicine (RM). (Professor Stokes- Turner 2010).
This summary slide sets out the business case and financial modelling for the commissioning of additional capacity for Level 2 Specialist Neuro-Rehabilitation Service (SNRS). The identified capacity resource needed to meet current recognised need is equivalent to a total of 19 SNRS Level 2 beds.
The proposed service model will provide a more flexible model of bed based and non-bed based/specialist outreach service to meet the varying needs for specialist neuro-rehabilitation for either bedded or community based interventions – linking both acute and community pathways.
The business case has identified that meeting this recognised need will result in immediate clinical and economic outcomes for patients across West London, Central London and Hammersmith and Fulham CCGs, namely:
• Provide positive patient experience by substantially reducing unwarranted delay to their next phase of care • Reduce additional cost in the acute hospital costs associated with increased length of stay in hospital • Measurable improvement in patent outcomes due to improved functional gain as a result of timely
interventions and reductions avoidable complications; • Quantifiable reduction in long-term (continuing care) costs due to a measurable reduction in the person’s
weekly on-going care costs. • Supporting transitions in care back to localities following rehabilitation.
Executive Summary: introduction
4
Add
Currently state:
• 10 commissioned SNRS block beds across the Triborough. This is currently being provided at the Albany Unit, Queens Square, London and provided by the University College of London Hospitals Foundation Trust (UCLH).
• Significant and increasing Delayed Transfers Of Care (DTOC) in hospitals – 6 to 10 weeks
• DTOC not only impacts on patient experiences of care, but also reduces the benefits to be gained from early intervention on reducing dependency levels
• Ad hoc out of area spot purchasing , and lost of opportunity in enhancing clinical outcomes and reducing longer term cost for on-going care.
Future state:
Financial Model quantifies the capacity and investment required to provide a clinical and cost efficient model of care which will significantly reduce:
• DTOC pressures and acute bed days lost for this patient cohort by 85%
• Reduce dependency levels leading to reductions in on-going care costs by atleast £481 per week per patient.
This is a first step in understanding and monitoring demand and capacity required for this cohort of patients. This is due to lack of complete data. However there is sufficient data set on neuro-rehab demand and delays to analyse, extrapolate and to make an informed estimation on current demand. This is explained in slides 7 and 8 onwards.
Executive summary: demand & capacity
5
Add The Business Case for additional capacity has been determined through extensive sector work - coordinated through Imperial College Health Partners (ICHP) – the designated regional clinical and academic science network involving:
• Patients and their families/carers, and representative groups e.g. Health Watch
• Clinical input from a range of clinicians, practitioners and managers across Acute Hospital Trusts, Clinical Commissioning Groups, Community Health Care providers,
• Adult Social Care, and Third Sector (Headway)
The following four options were examined in the business case are:
• Do nothing and maintain the status quo;
• Commission 19 additional SNRS beds resource to provide both a bedded and non-bedded/ Community Outreach model of care within the Triborough CCGs areas;
• Commission 19 additional SNRS beds within the Triborough area plus the 10 beds currently at the Albany Rehabilitation Unit;
• Undertake a whole service redesign of the full care pathway.
This business case recommends option 2 – to commission additional capacity equivalent to 19 SNRS Level 2 beds resource to meet the current and future demand requirements. This will ensure the provision of flexible model
of care to meet the varying needs for specialist neuro-rehabilitation.
Executive summary: engagement & recommendation
6
Add Business Case on a Page – patient flows
Long Acute Hospital stays
Home
Longer waits in Hospital for limited Out of Area Level 2
provision
Longer LOS Reduced outcomes
Local level 2 Specialist Neuro-Rehab Service
(SNRS) Beds
Transfer to local community based Specialist Neuro-Rehab Outreach
Service (SNROS) Level 2
Nursing Home
Community Independence Services (CIS) and Community Rehab Teams (CRTs)
Long-term care in Independent Hospitals
Key:
Community
CIS/CRTs
Hospital
Nurs/Res Care
Existing flows to reduced benefits = costs
New flows to increase benefits = reduce costs
Black arrows show current flows for most patients requiring bedded Neuro-rehab
Increased dependency &
avoidable complications
Reduced wait & Timely transfer
Local Neuro Rehab
Reduced dependency & improved outcomes
7
Add
Costs Benefits
Model Methodology – Index / Summary
Neuro Rehab
DTOC patients
Neuro Rehab
DTOC patients
(ICHT)
Neuro Rehab
DTOC patients
(Chelwest)
Required Level
2 Beds
Cost of Neuro
Rehab Level 2
Bed
Average Bed days
lost per DTOC
Savings from avoiding a
DTOC (DTOC cost
reduction)
1
2
3
Financial
Summary
Neuro Rehab
DTOC patients
Savings in
Long-term care
costs (weekly) 4
8
Add
Calculate the number of neuro
rehabilitation DTOC patients
Data sources :
•ICHT DTOC data (13-14 and 14-15)
•National DTOC data
Calculate required number of neuro
rehabilitation beds
Commissioner Assumptions:
•Bed occupancy rates
•LOS
Calculate the cost of a Level 2 neuro
rehabilitation bed
Benchmarking analysis
•National Tariff
•Level 2 Guide base rates
•OBD shadow tariff (Putney)
ARU Contractual value (10 beds)
Methodology for calculating – DTOC, beds & costs
1
2
3
9
Add 1) Calculating the number of Neuro rehabilitation DTOC patient numbers
ICHT Neuro Rehab DTOC Data
(13/14)
Imperial Chelwest
81 28
Estimated ChelWest 14/15
Neuro Rehab DTOC patients
Chelwest
26
Total Triborough Estimated
Neuro Rehab DTOC Patients
14/15
Imperial Chelwest
77 26
Total: 103
Assumption
*34.6%
Known Data
Key:
*34.6% calculated from comparing total number of Neuro
Rehab DTOCs from ChelWest to those from ICHT based on
2013/2014 data and methodology.
• Imperial Neuro-Rehab DTOC patients 13/14 – 81
• Chelwest Neuro-Rehab DTOC patients 13/14 - 28
• Calculation : 81/28= 0.346 (34,6%)
ICHT Neuro Rehab DTOC
Patients Data (14/15)
(prorated for full year)
Imperial
77
ICHT Neuro Rehab DTOC
Patients Data (8 months
in 14/15)
Imperial
51
Extrapolated using
monthly averages
10
Add
2) Calculating the number of neuro rehabilitation beds required to reduce DTOC’s
Length of Stay Target bed occupancy
rate
Neuro Beds required
56 85% 19 (18.6)
Assumption
Known Data
Key: Calculation:
• ((Total neuro rehab DTOC’s* LOS)/ Target Occupancy)/365
• ((103*56) / 85%)/ 365
103
Neuro Rehabilitation
DTOC (2014/15)
*LOS and occupancy rate : Standard Occupancy rate
assumptions for Level 2 bed unit, based on Albany Unit
information – provided by Ray Boateng
11
Add Average benchmark analysis - £3,605 per week:
• Calculating the average cost of current provision and 14-15 national tariff plus MFF: National tariff (£3,715 per week)
• Hospital based Level 2 beds guide base rate (Hillingdon Hospitals – Alderbourne and Mount Vernon units, Albany unit £2,741 per week)
• Occupied Bed Day for Independent hospital (Putney) - £4,359 per week
The average cost provides basis for market testing.
Commissioning envelope - £3715 per week
Recommended that the commissioning investment based on conservative scenario to be based National Tariff Plus MFF. Therefore commissioning financial envelope:
• 19 beds x £3,715 weekly bed cost x 52 weeks = £3,591,340
• Weekly rate per bed = £531
3) Calculate the cost of a Level 2 Neuro-rehab bed
12
Add Summary methodology for investment
Investment
Patients experiencing DTOC for neuro rehabilitation (Imperial and Chelwest)
103
Average LOS Level 2 Rehab bed 56
Assumed target bed occupancy 85%
Total shortage of beds 19
14-15 National Tariff + MFF for Level 2 cost (weekly cost per bed) £3,715
Additional required 19 Neuro Beds cost £3,591,340
Benchmark Analysis
1
2
3
1
2
3
Calculate the number of neuro rehabilitation DTOC patients
Calculate required number of neuro rehabilitation beds
Calculate the cost of a Level 2 neuro rehabilitation bed
13
Add Benefits Methodology
Calculate the number of neuro
rehabilitation DTOC patients per
provider
Data sources :
•ICHT DTOC data (13-14 and 14-15)
•National DTOC data
Calculate average bed days lost per
DTOC
Data sources and assumptions:
•ICHT and National DTOC data (13-14 and 14-15)
•85% reduction target on DTOCs
Calculate the cost of a DTOC (neuro
rehabilitation)
Rehabilitation cost analysis
•Triborough Data
•Cost of £282 per bed day
Calculate Long-term Care savings
due to neuro rehab
Source: 2005 research studies evidencing reduction in on-going care: £481 per week.
This is used as conservative estimate.
National benchmarking average from 2012 – 2014/15 suggest saving to be £534
1
2
3
4
14
Add 3) Calculate cost of a DTOC - Benefits Breakdown
Imperial DTOC
Savings (£274,574)
ChelWest DTOC
Savings (£95,095)
Total Benefits
(£369,669)
77 Patients at
£282/day for
15 DTOC days at 85% reduction rate
77 x 282 x 15 x 85% = £274,574
26 Patients at
£282/day for
15 DTOC days at 85% reduction rate
26 x 282 x 15 x 85% = £95,095
£282/day for DTOC derived from cost data set provided by H&F CCG (Sharon Robson)
15 days is average DTOC, calculated from a two year average calculation of Imperial patients experiencing
DTOC (see slide 7) divided by the total number of DTOC days they experienced.
15
Add 2) Calculate average bed days lost due to DTOC
Average Bed days lost per DTOC Final Two year average Bed
days lost per DTOC
(*) 2013-2014 (*) 2014-2015 13-14 and 14-15 data
19.6 10.4 15.0
(*) Methodology:
• Total Bed days lost / Number of DTOC patients
85% reduction rate of total DTOC bed days
12 (12.7)
16
Add Financial Summary of Benefits - DTOC
Benefits (*)
Patients experiencing DTOC for neuro rehabilitation (Imperial) 77
Average bed days 15.0
% Reduction of total DTOC (assumption) 85%
Average DTOC cost per bed (daily) £282
Savings from reduced DTOC (Imperial) -£274,574
Patients experiencing DTOC for neuro rehabilitation (Chelwest) 26
Average bed days 15.0
% Reduction of total DTOC (assumption) 85%
Average DTOC cost per bed (daily) £282
Savings from reduced DTOC (ChelWest) (*) -£95,095
1
2
3
1
2
3
1
2
3
Calculate the number of neuro rehabilitation DTOC patients per provider Calculate average bed days lost per DTOC
Calculate the cost of a DTOC (neuro rehabilitation)
* Note on Chelwest DTOC savings: Reflected to show financial impact, but savings have already been identified in other WL CCG QIPP schemes, quantifying DTOC savings (WL003)
17
Add 4) Financial Summary – savings on on-going care
Evidence from research Study 1 (See Business Case: Turner Stokes et. al, 2005) show that in 2005 the mean
average for long-term care cost saving impact following a specialist neuro-rehabilitation intervention was £481 per
week per patient – due to the reduction in dependency levels. This is what has been used for the business case.
Current UK Rehabilitation Outcomes Collaborative (UKROC) benchmarking data (see appendix – slide 28) show that
the 3 year mean average from 2012/13 – 2014/15 is £534 per week. Therefore the calculations for long-term care
savings are very prudent and conservative. (see appendix)
The table below provides a 3 years projection on the minimum cumulative financial impact on long-term savings for
the SRNS supporting a projected average of 103 patients each year – assuming each patient survives during the 3
year period. The projected long-term cost savings for the 3 year contract life is estimated at £15.5m
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117444/
Long-term care (LTC)
savings per year Patients 2016/2017 2017/2018 2018/2019 Total impact
LTC savings Year 1 103 £2,576,102 £2,576,102 £2,576,102 £7,728,307
LTC savings Year 2 103 £2,576,102 £2,576,102 £5,152,204
LTC saving Year 3 103 £2,576,102 £2,576,102
Total LTC savings 309 £2,576,102 £5,152,205 £7,728,307 £15,456,613
DTOC savings per year £369,669 £369,669 £369,669 £1,109,007
Total financial benefit 309 £2,945,771 £5,521,874 £8,097,976 £16,565,621
CCGs investments per Year £3,591,340 £3,591,340 £3,591,340 £10,774,020
Net costs(+)/benefits (-) +£645,568 -£1,930,534 -£4,506,636 -£5,791,601
18
Add
FUNDING ARRANGEMENTS
Options appraisal for funding
split per CCG
19
Add Options for funding split
1) Equal 3 way split
2) % split based on Albany usage for 14/15 - CL (37%), WL (36%), H&F (27%)
3) % split based on Albany usage 2yr average (2013 -14 /15) : CL (41.5%), WL (36%), H&F ( 22.5%). Please note 2013/14 usage - CL (46%), WL (36%), H&F (18%)
4) % split based on Imperial DTOC for 14-15 – DTOC % till Feb 2015 are 40% HF, 38% CL , and WL 22% (this is heavily weighted against HF)
5) Combined averages for options 3 and 4
OPTION 1 OPTION 2 OPTION 3 OPTION 4 OPTION 5
CCG Equal Split Activity Activity - 2 yr
Avg DTOC
Ratio (Option 3&4)
CL 33.33% 37.00% 41.50% 38.00% 39.75%
WL 33.33% 36.00% 36.00% 22.00% 29.00%
H&F 33.33% 27.00% 22.50% 40.00% 31.25%
20
Add OPTION 1
• As was recommended in the latest edition of the Business Case, a three way CCG split is the most sensible and pragmatic approach for initial investment. This simplicity of this can be re-balanced based on actual usage activity. CCG Finance Leads may accrue up to an additional 20% (as worst case scenario) and re-evaluate financial positions once activity data became available.
OPTIONS 2 (Albany usage % for 2013/14 ) & OPTION 3 (Albany usage % for 2013/14 – 2015/16)
• Albany does not provide for the full spectrum of Level 2 beds – therefore data on usage is only useful for understanding demand for certain patient cohorts only e.g Stroke patients.
• Whereas this may provide Central and West London CCGs with some indication of their usage, access is limited for H&F CCG - therefore provides only a partial indication of demand for H&F in addition to the limitations above. This is especially the case for 2013-2014 period.
OPTION 4
• National DTOC reporting categorises Neuro-delays under Category C – Further Non-acute NHS care. Category C includes NHS Cont Care and End of Life Care etc. Therefore ICHT data accurately captures the totality of neuro-delays. ICHT is also the biggest referrer for Neuro-rehab.
• However, the ICHT DTOC data for neuro-rehab is heavily weighted towards H&F CCG in particular – as patients are unlikely to end up in Chelwest. Monthly neuro - DTOC from Chelwest is unavailable.
Caveats – Limitations
21
Add Option 1) Equal Three way split: Financial Summary (2016-2017)
2016/2017 FYE H&F WL CL Total Drivers
Current Investment (15/16)
£418,845 £1,278,238 £1,011,490 £2,708,573 2015/2016 full year investment identified for SNRS resource
New Investment (16/17)
£778,264 -£81,125 £185,623 £882,767 2016/2017 additional FYE investment for SNRS resource
Total Investment (16/17)
£1,197,113 £1,197,113 £1,197,113 £3,591,340 2016/2017 full year investment for SNRS resource
Gross Benefits (DTOC)
-£123,223 -£123,223 -£123,223 -£369,669 Reduction in DTOCs
Total Net Investment
£1,073,890 £1,073,890 £1,073,890 £3,221,670 Time Frame : April 2016 - Mar 2017
The full year financial investments for 2016/17 are set below. This is a three way split part year effect, and will be rebased at the end of year based on usage.
CCG Equal Split Activity Activity - 2 yr
Avg DTOC Ratio
CL 33.33% 37.00% 41.50% 38.00% 39.75%
WL 33.33% 36.00% 36.00% 22.00% 29.00%
H&F 33.33% 27.00% 22.50% 40.00% 31.25%
22
Add Option 2) Albany Activity usage Split (2013/14): Financial Summary (2016-2017)
2016/2017 FYE H&F WL CL Total Drivers
Current Investment (15/16)
£418,845 £1,278,238 £1,011,490 £2,708,573 2015/2016 full year investment identified for SNRS resource
New Investment (16/17)
£550,813 £14,644 £317,306 £882,767 2016/2017 additional FYE investment for SNRS resource
Total Investment (16/17)
£969,662 £1,292,882 £1,328,796 £3,591,340 2016/2017 full year investment for SNRS resource
Gross Benefits (DTOC)
-£99,811 -£133,081 -£136,778 -£369,669 Reduction in DTOCs
Total Net Investment
£869,851 £1,159,801 £1,192,018 £3,221,670 Time Frame : April 2016 - Mar 2017
The full year financial investments for 2016/17 are set below. This is an option that represents funding arrangements based on Albany Rehabilitation Unit Activity
CCG Equal Split Activity Activity - 2 yr
Avg DTOC Ratio
CL 33.33% 37.00% 41.50% 38.00% 39.75% WL 33.33% 36.00% 36.00% 22.00% 29.00%
H&F 33.33% 27.00% 22.50% 40.00% 31.25%
23
Add Option 3 - 2 year Average Albany Activity usage: Financial Summary (2016-2017)
2016/2017 FYE H&F WL CL Total Drivers
Current Investment (15/16)
£418,845 £1,278,238 £1,011,490 £2,708,573 2015/2016 full year investment identified for SNRS resource
New Investment (16/17)
£389,207 £14,644 £478,916 £882,767 2016/2017 additional FYE investment for SNRS resource
Total Investment (16/17)
£808,051 £1,292,882 £1,490,406 £3,591,340 2016/2017 full year investment for SNRS resource
Gross Benefits (DTOC)
-£83,176 -£133,081 -£153,413 -£369,669 Reduction in DTOCs
Total Net Investment
£724,876 £1,159,801 £1,336,993 £3,221,670 Time Frame : April 2016 - Mar 2017
The full year financial investments for 2016/17 are set below. This is an option that represents funding arrangements based on Albany Rehabilitation Unit Activity (2 year period)
CCG Equal Split Activity Activity - 2 yr
Avg DTOC Ratio
CL 33.33% 37.00% 41.50% 38.00% 39.75%
WL 33.33% 36.00% 36.00% 22.00% 29.00% H&F 33.33% 27.00% 22.50% 40.00% 31.25%
24
Add Option 4) Split based on DTOC activity: Financial Summary (2016-2017)
2016/2017 FYE H&F WL CL Total Drivers
Current Investment (15/16)
£418,845 £1,278,238 £1,011,490 £2,708,573 2015/2016 full year investment identified for SNRS resource
New Investment (16/17)
£1,017,691 -£488,143 £353,219 £882,767 2016/2017 additional FYE investment for SNRS resource
Total Investment (16/17)
£1,436,536 £790,095 £1,364,709 £3,591,340 2016/2017 full year investment for SNRS resource
Gross Benefits (DTOC)
-£147,868 -£81,327 -£140,474 -£369,669 Reduction in DTOCs
Total Net Investment
£1,288,668 £708,768 £1,224,235 £3,221,670 Time Frame : April 2016 - Mar 2017
The full year financial investments for 2016/17 are set below. This is an option that represents funding arrangements based on DTOC Activity (ICHT)
CCG Equal Split Activity Activity - 2 yr
Avg DTOC Ratio
CL 33.33% 37.00% 41.50% 38.00% 39.75%
WL 33.33% 36.00% 36.00% 22.00% 29.00%
H&F 33.33% 27.00% 22.50% 40.00% 31.25%
25
Add Option 5) Combined averages split: Financial Summary (2016-2017)
2016/2017 FYE H&F WL CL Total Drivers
Current Investment (15/16)
£418,849 £1,278,238 £1,011,490 £2,708,573 2015/2016 full year investment identified for SNRS resource
New Investment (16/17)
£703,449 -£236,749 £416,068 £882,767 2016/2017 additional FYE investment for SNRS resource
Total Investment (16/17)
£1,122,294 £1,041,489 £1,427,558 £3,591,340 2016/2017 full year investment for SNRS resource
Gross Benefits (DTOC)
-£115,522 -£107,204 -£146,943 -£369,669 Reduction in DTOCs
Total Net Investment
£987,319 £1,036,039 £1,198,313 £3,221,670 Time Frame : April 2016 - Mar 2017
The full year financial investments for 2016/17 are set below. This is an option that represents funding arrangements based on an average of the three previous split options
CCG Equal Split Activity Activity - 2 yr
Avg DTOC Ratio
CL 33.33% 37.00% 41.50% 38.00% 39.75%
WL 33.33% 36.00% 36.00% 22.00% 29.00% H&F 33.33% 27.00% 22.50% 40.00% 31.25%
26
Add Governance approval timelines
Ops Group Submission Date Meeting Date
Central London TRG May 5th May 13th
West London Ops May 8th May 12th
H&F Ops May 8th May 12th
F&P Submission Date Meeting Date
Central London F&P May 18th May 27th
West London F&P May 18th May 26th
H&F F&P May 14th May 26th
Governing Body Submission Date Meeting Date
Central London GB June 29th July 8th
West London GB July 13th July 21st
H&F GB July 7th July 14th
27
Add Issue advert & ITT
documentation
Procurement advertised on Contracts Finder and all
procurement documents made available to potential Bidders
through the E-Procurement portal
Early August 2015
Bidder Briefing Event CCGs host a Bidder Briefing Event to ensure good understanding by
Bidders of the service requirements and Procurement process –
following market testing
Mid to late August 2015
Deadline for the receipt of
clarification questions
Deadline for Bidders to submit clarifications to the CCGs 1 week before ITT submission
deadline (see below) ITT Submission DEADLINE Deadline by when Bidders must have fully completed and submitted
their Bids – this presumes 7 weeks (can be shortened / lengthened)
End of September 2015
ITT Bid evaluation stage Period when Bids will be evaluated and CCG clarification questions
responded to by bidders. Evaluation panel individually review and
score bids, followed by moderation event to agreed consensus
scores and section of the Preferred Bidder(s)
Early October 2015 (allow 1 or 2
weeks), including Evaluation Panel
Moderation meeting immediately
toward end of this couple of weeks
Post procurement outcomes
report
Preparation of report detailing the evaluation approach and
outcome, with recommendation regarding award of contract
Mid October 2015
CCG authorisation to award
contract(s)
CCG governance to consider post-procurement recommendation
report regarding contract award. CCG authorise contract award.
By end of October 2015 – TBC
pending meeting dates
Preferred Bidder initial
notification and standstill
period regarding Confirmation
The expected dates when Bidders will be notified of the outcome of
the evaluation and observance of the recommended Standstill
Period
End of October 2015
Contract signature The expected date for the signing of the Contracts between the
CCGs and the successful Provider
From mid-November 2015
Service mobilisation period Period when the Preferred Bidder plans and delivers mobilisation
activities to prepare for service commencement
From November 2015 – duration
dependent upon mobilisation plan
TBA with preferred bidder –
assume at least 3 or 4 months Full service commencement Date when commencement of the new Services expected 1st April 2016 possible
Procurement timelines
28
Add
APPENDIX Additional slides
29
Add Levels of need & service categories/levels
30
Add The national benchmarking data set below supports both the clinical impact/outcomes
(measurable functional gains), as well as the economic impact (measurable reduction in on-
going care) that specialist neuro-rehabilitation service make.
National /ARU benchmarking summary data evidencing clinical & economic impact of SNRS
31
Add
Source: UK Rehabilitation Outcomes Collaborative (UK ROC)
National /ARU benchmarking summary data evidencing clinical & economic impact of SNRS